TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Managing Weight in Overweight and At-Risk Children
Brief Summary: The prevalence of overweight children has increased significantly over the past 3 decades and 3 out of every 4 overweight children become obese adults. Additionally, overweight children are now at risk for developing type-2 diabetes while still in their youth. To address the issue of childhood weight management, Golan and colleagues provided a model for intervention development that targets parents as an exclusive agent of change when attempting to treat weight issues for children under 12 years of age. The Kaiser Permanente Colorado (KPCO) Weight Management Program (WMP) developed Family Connections, a condensed two-session program, based on the Golan model, for parents of children between the ages of 8-12 with a Body Mass Index (BMI) greater than the 85 percentile for age and gender. There is a need to determine if the content of Golan's model can be translated into a practical intervention to be used in usual pediatric weight management practice. The Family Connections study uses three arms to determine the effectiveness of healthy eating and active living messages.


Options:
A: Arm Label: Standard Care with Education Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Arm Label: Moderate Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Dose Motivational Interviewing | Arm Label: Higher Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Higher Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care with Education Materials | Intervention Type: BEHAVIORAL; Name: Moderate Dose Motivational Interviewing; Assigned to Arm(s): Moderate Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Higher Dose Motivational Interviewing; Assigned to Arm(s): Higher Dose Motivational Interviewing
B: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
C: Arm Label: A: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (B): experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (c): experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (D): control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Obesity-Children | Intervention Type: BEHAVIORAL; Name: Obesity-Children; Assigned to Arm(s): (B): experimental, (D): control group, (c): experimental, A: experimental
D: Intervention Type: BEHAVIORAL; Name: Targeted parental instruction for positive lifestyle change with follow-up calls.; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.
Brief Summary: The FIRE-3 trial is a multicenter randomized phase III trial investigating 5-FU, folinic acid and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment of metastatic colorectal cancer. Planned accrual is 284 evaluable patients per treatment arm. The primary study endpoint is objective response rate. Secondary endpoints are median progression free survival, median overall survival, safety, and secondary resection rate.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Drug: folinic acid, Drug: irinotecan, Drug: cetuximab | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Drug: folinic acid, Drug: irinotecan, Drug: bevacizumab | Intervention Type: DRUG; Name: 5-FU; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Arm B
D: Arm Label: bevacizumab alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: Bevacizumab + erlotinib; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab alone | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): Bevacizumab + erlotinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™)
Brief Summary: The primary objectives of the trial are:

1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing a primary angioplasty strategy.
2. To establish the safety and efficacy of the slow rate release paclitaxel-eluting TAXUS™ stent compared to an otherwise identical uncoated bare metal EXPRESS2™ stent.


Options:
A: Arm Label: XIENCE V®; Type: EXPERIMENTAL; Interventions: Device: XIENCE V® Everolimus Eluting Coronary Stent | Arm Label: TAXUS™ EXPRESS2™; Type: ACTIVE_COMPARATOR; Interventions: Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent | Intervention Type: DEVICE; Name: XIENCE V® Everolimus Eluting Coronary Stent; Assigned to Arm(s): XIENCE V® | Intervention Type: DEVICE; Name: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent; Assigned to Arm(s): TAXUS™ EXPRESS2™
B: Arm Label: Everolimus Arm; Type: EXPERIMENTAL; Interventions: Drug: Everolimus Eluting Coronary Stent System | Arm Label: non drug eluting stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: cobalt chromium balloon expandable stent ( non drug eluting stent Arm) | Intervention Type: DRUG; Name: Everolimus Eluting Coronary Stent System; Assigned to Arm(s): Everolimus Arm | Intervention Type: DEVICE; Name: cobalt chromium balloon expandable stent ( non drug eluting stent Arm); Assigned to Arm(s): non drug eluting stent Arm
C: Arm Label: Pharmacology Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bivalirudin, Drug: Unfractionated heparin | Arm Label: Stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent, Device: Paclitaxel-eluting stent | Intervention Type: DRUG; Name: Bivalirudin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Pharmacology Arm | Intervention Type: DEVICE; Name: Bare metal stent; Assigned to Arm(s): Stent Arm | Intervention Type: DEVICE; Name: Paclitaxel-eluting stent; Assigned to Arm(s): Stent Arm
D: Arm Label: Drug Eluting Absorbable Metal Scaffold; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention (DREAMS) stenting | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention (DREAMS) stenting; Assigned to Arm(s): Drug Eluting Absorbable Metal Scaffold

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Brief Summary: The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with illumination in different spectral bands, from visible to near infrared, and automatically analyzes these images. Diagnostic accuracy of MelaFind® and that of study dermatologists will be evaluated. The reference standard will be final interpretation of lesions by central dermatohistopathology.


Options:
A: N/A
B: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
C: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
D: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Brief Summary: The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with illumination in different spectral bands, from visible to near infrared, and automatically analyzes these images. Diagnostic accuracy of MelaFind® and that of study dermatologists will be evaluated. The reference standard will be final interpretation of lesions by central dermatohistopathology.


Options:
A: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
B: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
C: N/A
D: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Brief Summary: The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with illumination in different spectral bands, from visible to near infrared, and automatically analyzes these images. Diagnostic accuracy of MelaFind® and that of study dermatologists will be evaluated. The reference standard will be final interpretation of lesions by central dermatohistopathology.


Options:
A: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
B: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
C: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Arm Label: Reflectance confocal microscopy (RCM); Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): Reflectance confocal microscopy (RCM) | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): Reflectance confocal microscopy (RCM), Standard of care procedure

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Brief Summary: The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with illumination in different spectral bands, from visible to near infrared, and automatically analyzes these images. Diagnostic accuracy of MelaFind® and that of study dermatologists will be evaluated. The reference standard will be final interpretation of lesions by central dermatohistopathology.


Options:
A: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
B: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
C: Arm Label: Nevi from participants; Type: EXPERIMENTAL; Interventions: Genetic: To test the frequency of BRAF and NRAS mutations among nevi | Intervention Type: GENETIC; Name: To test the frequency of BRAF and NRAS mutations among nevi; Assigned to Arm(s): Nevi from participants
D: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
Brief Summary: * to demonstrate the superiority of Trexima (combination of sumatriptan as the succinate 85 mg and naproxen sodium 500 mg) versus placebo in the acute treatment of migraine
* to demonstrate the superiority of Trexima versus the individual components (sumatriptan as the succinate 85 mg and naproxen sodium 500 mg), and
* to evaluate the safety of the Trexima.


Options:
A: Arm Label: TPB; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: TBP; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: BTP; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: BPT; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: PTB; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: PBT; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Intervention Type: DRUG; Name: TREXIMET®; Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB | Intervention Type: DRUG; Name: Butalbital-containing Combination Medications (BCM); Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treximet | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Migraine rescue medication of choice | Intervention Type: DRUG; Name: Treximet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Migraine rescue medication of choice; Assigned to Arm(s): 2
C: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: sumatriptan succinate/naproxen sodium | Arm Label: arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: sumatriptan succinate/naproxen sodium; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): arm 2
D: Intervention Type: DRUG; Name: sumatriptan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naproxen sodium; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).
Brief Summary: This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.


Options:
A: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
B: Arm Label: Methylphenidate Transdermal System; Type: EXPERIMENTAL; Interventions: Drug: Daytrana | Intervention Type: DRUG; Name: Daytrana; Assigned to Arm(s): Methylphenidate Transdermal System
C: Arm Label: A; Type: N/A; Interventions: Drug: Atomoxetine | Arm Label: B; Type: N/A; Interventions: Drug: stimulants (any approved ADHD medication) | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: stimulants (any approved ADHD medication); Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes
Brief Summary: The purpose of this study is to determine if a randomized trial of physical therapy for pelvic pain is feasible.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: combined sono-electro-magnetic therapy (Sonodyn Medico Star) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo therapy (Placebo Sonodyn Medico Star) | Intervention Type: DEVICE; Name: combined sono-electro-magnetic therapy (Sonodyn Medico Star); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: placebo therapy (Placebo Sonodyn Medico Star); Assigned to Arm(s): 2
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A
D: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes
Brief Summary: The purpose of this study is to determine if a randomized trial of physical therapy for pelvic pain is feasible.


Options:
A: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
B: Arm Label: JNJ-42160443; Type: EXPERIMENTAL; Interventions: Drug: JNJ-42160443 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-42160443; Assigned to Arm(s): JNJ-42160443
C: Arm Label: ASP6294; Type: EXPERIMENTAL; Interventions: Drug: ASP6294 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP6294; Assigned to Arm(s): ASP6294 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: PD 0299685 15mg; Type: EXPERIMENTAL; Interventions: Drug: PD 0299685 at 15mg BID | Arm Label: PD 0299685 30mg; Type: EXPERIMENTAL; Interventions: Drug: PD 0299685 at 30mg BID | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for PD 0299685 | Intervention Type: DRUG; Name: PD 0299685 at 15mg BID; Assigned to Arm(s): PD 0299685 15mg | Intervention Type: DRUG; Name: PD 0299685 at 30mg BID; Assigned to Arm(s): PD 0299685 30mg | Intervention Type: DRUG; Name: placebo for PD 0299685; Assigned to Arm(s): Placebo

Answer: A